Revenue growth of 27% for full year 2025 was driven by continued penetration of the VA hospital system and a 93% surge in Truvaga wellness sales. The VA channel remains the primary revenue driver, currently reaching approximately 13,400 patients, which management estimates is only 2% of the addressable VA headache market. Strategic shift in the direct-to-consumer segment toward the company's own e-commerce site improved Return on Advertising Spend (ROAS) to $2.10 in Q4. The acquisition of Quell asse ...